Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Protagonist Therapeutics

Nasdaq:PTGX
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PTGX
Nasdaq
$175M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Protagonist Therapeutics has significant price volatility in the past 3 months.
PTGX Share Price and Events
7 Day Returns
13.6%
NasdaqGM:PTGX
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-48.9%
NasdaqGM:PTGX
1.6%
US Biotechs
-9.1%
US Market
PTGX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Protagonist Therapeutics (PTGX) 13.6% -17.9% -8.3% -48.9% -49.9% -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • PTGX underperformed the Biotechs industry which returned 1.6% over the past year.
  • PTGX underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
PTGX
Industry
5yr Volatility vs Market
Related Companies

PTGX Value

 Is Protagonist Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Protagonist Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $6.42.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Protagonist Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Protagonist Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:PTGX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.98
NasdaqGM:PTGX Share Price ** NasdaqGM (2020-03-27) in USD $6.42
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Protagonist Therapeutics.

NasdaqGM:PTGX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PTGX Share Price ÷ EPS (both in USD)

= 6.42 ÷ -2.98

-2.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protagonist Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Protagonist Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Protagonist Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:PTGX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
19.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Protagonist Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Protagonist Therapeutics's assets?
Raw Data
NasdaqGM:PTGX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.94
NasdaqGM:PTGX Share Price * NasdaqGM (2020-03-27) in USD $6.42
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:PTGX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PTGX Share Price ÷ Book Value per Share (both in USD)

= 6.42 ÷ 2.94

2.19x

* Primary Listing of Protagonist Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protagonist Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Protagonist Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Protagonist Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PTGX Future Performance

 How is Protagonist Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Protagonist Therapeutics expected to grow at an attractive rate?
  • Protagonist Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Protagonist Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Protagonist Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:PTGX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:PTGX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 19.9%
NasdaqGM:PTGX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 53.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:PTGX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:PTGX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 149 -23 24 4
2023-12-31 64 -48 -64 4
2022-12-31 31 -69 -77 5
2021-12-31 26 -60 -68 5
2020-12-31 11 -75 -77 5
2020-03-28
NasdaqGM:PTGX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -42 -77
2019-09-30 0 -37 -74
2019-06-30 2 -32 -66
2019-03-31 22 -51 -45
2018-12-31 31 -50 -39
2018-09-30 40 -54 -28
2018-06-30 43 -4 -24
2018-03-31 31 -1 -31
2017-12-31 20 4 -37
2017-09-30 9 8 -45
2017-06-30 -39 -48
2017-03-31 -35 -40

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Protagonist Therapeutics's earnings are expected to grow by 19.9% yearly, however this is not considered high growth (20% yearly).
  • Protagonist Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:PTGX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Protagonist Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PTGX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.02 1.46 -1.61 4.00
2023-12-31 -1.86 -1.08 -3.34 4.00
2022-12-31 -2.23 -1.40 -3.97 5.00
2021-12-31 -2.04 -1.43 -3.55 5.00
2020-12-31 -2.69 -2.39 -3.28 5.00
2020-03-28
NasdaqGM:PTGX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.98
2019-09-30 -2.94
2019-06-30 -2.74
2019-03-31 -1.96
2018-12-31 -1.74
2018-09-30 -1.32
2018-06-30 -1.22
2018-03-31 -1.62
2017-12-31 -2.09
2017-09-30 -2.68
2017-06-30 -3.24
2017-03-31 -3.77

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Protagonist Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Protagonist Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Protagonist Therapeutics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PTGX Past Performance

  How has Protagonist Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Protagonist Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Protagonist Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Protagonist Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Protagonist Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Protagonist Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Protagonist Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PTGX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.23 -77.19 15.75 65.00
2019-09-30 -0.14 -73.55 15.16 63.34
2019-06-30 1.84 -65.88 14.50 58.19
2019-03-31 21.70 -45.37 13.82 56.57
2018-12-31 30.93 -38.92 13.70 59.50
2018-09-30 39.85 -28.11 13.25 56.97
2018-06-30 42.52 -24.20 12.48 56.00
2018-03-31 30.84 -30.52 12.43 50.27
2017-12-31 20.06 -36.96 11.78 46.18
2017-09-30 8.78 -45.15 11.28 43.28
2017-06-30 -47.71 10.27 37.67
2017-03-31 -40.05 8.54 31.36
2016-12-31 -37.74 6.96 25.71
2016-09-30 -32.02 5.20 21.08
2016-06-30 -28.13 4.48 18.67
2016-03-31 -24.02 3.87 15.27
2015-12-31 -14.93 2.96 11.83
2014-12-31 -11.22 1.86 7.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Protagonist Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Protagonist Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Protagonist Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Protagonist Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Protagonist Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PTGX Health

 How is Protagonist Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Protagonist Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Protagonist Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Protagonist Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Protagonist Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 14.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Protagonist Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:PTGX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 79.96 9.79 133.02
2019-09-30 95.36 0.00 137.69
2019-06-30 84.32 0.00 126.10
2019-03-31 100.83 0.00 112.55
2018-12-31 112.52 0.00 128.85
2018-09-30 123.96 0.00 138.52
2018-06-30 107.66 0.00 125.17
2018-03-31 114.62 0.00 134.96
2017-12-31 120.63 0.00 144.00
2017-09-30 57.84 0.00 93.59
2017-06-30 61.03 0.00 64.49
2017-03-31 74.89 0.00 63.25
2016-12-31 87.56 0.00 77.60
2016-09-30 97.49 0.00 98.52
2016-06-30 20.41 0.00 20.18
2016-03-31 27.39 0.00 29.02
2015-12-31 11.72 0.00 11.92
2014-12-31 8.98 0.00 9.32
  • Protagonist Therapeutics's level of debt (12.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Protagonist Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Protagonist Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Protagonist Therapeutics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 23.4% each year.
X
Financial health checks
We assess Protagonist Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Protagonist Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PTGX Dividends

 What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Protagonist Therapeutics dividends.
If you bought $2,000 of Protagonist Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Protagonist Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Protagonist Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:PTGX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:PTGX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Protagonist Therapeutics has not reported any payouts.
  • Unable to verify if Protagonist Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Protagonist Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Protagonist Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Protagonist Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Protagonist Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Protagonist Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PTGX Management

 What is the CEO of Protagonist Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dinesh Patel
COMPENSATION $3,721,511
AGE 62
TENURE AS CEO 11.3 years
CEO Bio

Dr. Dinesh V. Patel, Ph.D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and was its Interim Chief Financial Officer till May 28, 2019. Dr. Patel serves as secretary of Protagonist Therapeutics, Inc. He is also Interim Principal Accounting Officer of Protagonist Therapeutics, Inc. Dr. Patel served as Consultant of Arête Therapeutics, Inc. since July 2008. He served as Chief Executive of Arête Therapeutics Inc., from February 2006 to July 2008 and also served as its President since 2006 until July 2008. Dr. Patel Co-founded Miikana Therapeutics Inc., in 2002 and served as its President from 2003 to 2005 and served as its Chief Operating Officer. He served as Senior Vice President of drug discovery and licensing of Vicuron Pharmaceuticals Inc., (formerly, Versicor) since 1996 until July 2003. Dr. Patel has over 18 years of experience in the pharmaceutical, biotech and biopharmaceutical industry. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2015), from 1996 to 2003. At Versicor, he led their internal and collaborative research programs (Pharmacia, Novartis) and actively participated in various financing activities. Dr. Patel served as Director of Drug Discovery of Affymax and led the combinatorial chemistry application efforts aimed at changing the drug discovery paradigm. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1193 and served in various positions including group leader. Dr. Patel has a proven track record of incubating and leading projects from ‘Targets to INDs’. He serves as a Director of Protagonist Therapeutics, Inc. since December 2008. He served as Director of Arête Therapeutics, Inc. until July 2008. He has more than 100 patents and publications to his credit. Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Prior to that, he was the Chief Executive Officer of Miikana Therapeutics, an oncology-based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Dr. Patel has more than 30 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Dr. Patel received his Ph.D. in Organic Chemistry from Rutgers, The State University of New Jersey and conducted Post-Doctoral research at the University of Wisconsin, Madison. He holds B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

CEO Compensation
  • Dinesh's compensation has increased whilst company is loss making.
  • Dinesh's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Protagonist Therapeutics management team in years:

3.2
Average Tenure
61.5
Average Age
  • The tenure for the Protagonist Therapeutics management team is about average.
Management Team

Dinesh Patel

TITLE
CEO, President
COMPENSATION
$4M
AGE
62
TENURE
11.3 yrs

Richard Shames

TITLE
Clinical Advisor
COMPENSATION
$1M
AGE
59
TENURE
4.6 yrs

David Liu

TITLE
Chief Scientific Officer and Head of Research & Development
COMPENSATION
$2M
AGE
69
TENURE
6.8 yrs

Don Kalkofen

TITLE
Chief Financial Officer
AGE
55
TENURE
0.8 yrs

Sam Saks

TITLE
Chief Medical Officer
AGE
64
TENURE
1.8 yrs

Suneel Gupta

TITLE
Chief Development Officer
AGE
61
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Protagonist Therapeutics board of directors in years:

3.7
Average Tenure
59
Average Age
  • The tenure for the Protagonist Therapeutics board of directors is about average.
Board of Directors

Barry Selick

TITLE
Chairman
COMPENSATION
$132K
AGE
65

Dinesh Patel

TITLE
CEO, President
COMPENSATION
$4M
AGE
62
TENURE
11.3 yrs

Chaitan Khosla

TITLE
Director & Chairman of Scientific Advisory Board
COMPENSATION
$117K
AGE
54

Will Waddill

TITLE
Independent Director
COMPENSATION
$109K
AGE
62
TENURE
3.7 yrs

Bryan Giraudo

TITLE
Independent Director
COMPENSATION
$170K
AGE
43
TENURE
1.8 yrs

Charles Craik

TITLE
Scientific Advisor

Mark Gallop

TITLE
Scientific Advisor
AGE
56

Aida Habtezion

TITLE
Clinical Advisor

Wayne Lencer

TITLE
Clinical Advisor

Ellen Scherl

TITLE
Clinical Advisor
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Protagonist Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Mar 20 Buy Harold Selick Individual 12. Mar 20 12. Mar 20 12,000 $6.70 $80,400
03. Dec 19 Buy Suneel Gupta Individual 03. Dec 19 03. Dec 19 30,000 $5.13 $153,900
03. Dec 19 Buy Dinesh Patel Individual 03. Dec 19 03. Dec 19 30,000 $5.65 $168,500
03. Dec 19 Buy Bryan Giraudo Individual 03. Dec 19 03. Dec 19 8,000 $5.70 $45,620
03. Dec 19 Buy Donald Kalkofen Individual 03. Dec 19 03. Dec 19 1,175 $5.10 $5,987
08. Aug 19 Sell Dinesh Patel Individual 06. Aug 19 06. Aug 19 -10,792 $8.85 $-95,535
08. Aug 19 Sell David Liu Individual 06. Aug 19 06. Aug 19 -3,395 $8.85 $-30,044
X
Management checks
We assess Protagonist Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Protagonist Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PTGX News

Simply Wall St News

Before You Buy Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Consider Its Volatility

See our latest analysis for Protagonist Therapeutics What we can learn from PTGX's beta value Given that it has a beta of 1.76, we can surmise that the Protagonist Therapeutics share price has been fairly sensitive to market volatility (over the last 5 years). … If this beta value holds true in the future, Protagonist Therapeutics shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Protagonist Therapeutics tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

How Much Are Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Taking Off The Table?

So we'll take a look at whether insiders have been buying or selling shares in Protagonist Therapeutics, Inc. … It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. … The Last 12 Months Of Insider Transactions At Protagonist Therapeutics.

Simply Wall St -

The Protagonist Therapeutics Share Price Is Down 59% So Some Shareholders Are Wishing They Sold

Protagonist Therapeutics isn't yet profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … Protagonist Therapeutics grew its revenue by 354% over the last year.

Simply Wall St -

Before You Buy Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Consider Its Volatility

(NASDAQ:PTGX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?

So we'll take a look at whether insiders have been buying or selling shares in Protagonist Therapeutics, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … In any event it's generally a positive if insiders are buying shares at around the current price

Simply Wall St -

When Will Protagonist Therapeutics Inc (NASDAQ:PTGX) Become Profitable?

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. … With the latest financial year loss of -US$37.0m and a trailing-twelve month of -US$28.1m, the US$202m market-cap alleviates its loss by moving closer towards its target of breakeven? … View our latest analysis for Protagonist Therapeutics

Simply Wall St -

Protagonist Therapeutics Inc (NASDAQ:PTGX): When Will It Breakeven?

Protagonist Therapeutics Inc's (NASDAQ:PTGX):. … Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. … View out our latest analysis for Protagonist Therapeutics

Simply Wall St -

Protagonist Therapeutics Inc (NASDAQ:PTGX): When Will It Breakeven?

I’ve put together a brief outline of industry analyst expectations for PTGX, its year of breakeven and its implied growth rate. … See our latest analysis for Protagonist Therapeutics PTGX is bordering on breakeven, according to analysts. … How fast will PTGX have to grow each year in order to reach the breakeven point by 2020?

Simply Wall St -

Value-Adding Growth Stocks To Buy Now

PTGX’s projected future profit growth is a robust 40.01%, with an underlying triple-digit growth from its revenues expected over the upcoming years. … Profit growth, coupled with top-line expansion, is a positive indication. … Profit growth, coupled with top-line expansion, is a positive indication.

Simply Wall St -

PTGX Company Info

Description

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn’s disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.

Details
Name: Protagonist Therapeutics, Inc.
PTGX
Exchange: NasdaqGM
Founded: 2006
$175,229,399
27,294,299
Website: http://www.protagonist-inc.com
Address: Protagonist Therapeutics, Inc.
7707 Gateway Boulevard,
Suite 140,
Newark,
California, 94560,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PTGX Common Stock Nasdaq Global Market US USD 11. Aug 2016
BST PGF Common Stock Boerse-Stuttgart DE EUR 11. Aug 2016
Number of employees
Current staff
Staff numbers
73
Protagonist Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:02
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/12
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.